Naltrexone–bupropion for managing overweight and obesity - guidance (TA494)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
12 December 2017

Abstract

Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: December 2020